Cargando…
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection
INTRODUCTION: Transcutaneous immunization (TCI) is a non-invasive vaccination method promoting strong cellular immune responses, crucial for the immunological rejection of cancer. Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic...
Autores principales: | Hartmann, Ann-Kathrin, Bartneck, Joschka, Pielenhofer, Jonas, Meiser, Sophie Luise, Arnold-Schild, Danielle, Klein, Matthias, Stassen, Michael, Schild, Hansjörg, Muth, Sabine, Probst, Hans Christian, Langguth, Peter, Grabbe, Stephan, Radsak, Markus P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505723/ https://www.ncbi.nlm.nih.gov/pubmed/37727790 http://dx.doi.org/10.3389/fimmu.2023.1238861 |
Ejemplares similares
-
Dithranol as novel co-adjuvant for non-invasive dermal vaccination
por: Sohl, Julian, et al.
Publicado: (2022) -
Author Correction: Dithranol as novel co-adjuvant for non-invasive dermal vaccination
por: Sohl, Julian, et al.
Publicado: (2023) -
Tumor-infiltrating CCR2(+) inflammatory monocytes counteract specific immunotherapy
por: Bartneck, Joschka, et al.
Publicado: (2023) -
Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product
por: Pielenhofer, Jonas, et al.
Publicado: (2023) -
Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation
por: Stein, Pamela, et al.
Publicado: (2014)